Coherus Oncology (CHRS) Profit After Tax Growth (3y) (2016 - 2026)

Coherus Oncology (CHRS) Profit After Tax Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 84.25%
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 33.21%
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 30.60%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 16.53%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -154.28%
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 13.80%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Coherus Oncology 199.14 Mn 32.09 Mn 8.50 Mn 21.28%

Historic Data

Download Data
DateValue
Mar 31, 2026 21.28%
Dec 31, 2025 7.66%
Sep 30, 2025 19.91%
Jun 30, 2025 99.48%
Mar 31, 2025 20.99%
Dec 31, 2024 -3.50%
Sep 30, 2024 34.65%
Jun 30, 2024 24.40%
Mar 31, 2024 37.42%
Dec 31, 2023 -116.90%
Sep 30, 2023 -50.65%
Jun 30, 2023 -39.70%
Mar 31, 2023 -60.43%
Dec 31, 2022 -51.84%
Sep 30, 2022 -56.62%
Jun 30, 2022 -60.42%
Mar 31, 2022 -68.72%
Dec 31, 2021 9.94%
Sep 30, 2021 13.16%
Jun 30, 2021 11.87%